[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"OncoHost Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":74},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100611913","neutrophil-biomarker-test-for-predicting-clinical-benefit-from-immunotherapy-based-on-flow-cytometry-analysis-100611913",false,"NCT07246759","Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis","NEUTROFLOW: Development and Validation of a Pan-cancer Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis of Blood Samples","NEUTROFLOW","Inclusion Criteria:\n\n• Patients newly diagnosed with advanced-stage\u002Fmetastatic NSCLC, melanoma, HNSCC, RCC, or TNBC, who are due to receive first-line treatment with a PD-(L)1 inhibitor, either as monotherapy or in combination with other agents, according to current standard-of-care regimens, including (but not limited to) the following approved options: NSCLC. Monotherapy: Pembrolizumab, Atezolizumab, Cemiplimab. Combination: Pembrolizumab + chemotherapy; Nivolumab + Ipilimumab; Cemiplimab + chemotherapy; Atezolizumab + chemotherapy + Bevacizumab.\n\nMelanoma. Monotherapy: Nivolumab, Pembrolizumab. Combination: Nivolumab + Ipilimumab; Nivolumab + Relatlimab.\n\nHNSCC. Monotherapy: Pembrolizumab, Cemiplimab. Combination: Pembrolizumab + chemotherapy.\n\nRCC. Combination only: Nivolumab + Ipilimumab; Nivolumab + Cabozantinib; Pembrolizumab + Lenvatinib or Axitinib; Avelumab + Axitinib.\n\nTNBC. Combination only: Pembrolizumab + chemotherapy.\n\n* Male or female aged at least 18 years\n* ECOG PS: 0\u002F1-2\n* Normal hematologic, renal and liver function:\n\nAbsolute neutrophil count \\> 1500\u002Fmm³ Platelets \\> 100,000\u002Fmm³ Hemoglobin \\> 9 g\u002FdL Creatinine concentration ≤ 1.4 mg\u002FdL, or creatinine clearance \\> 40 mL\u002Fmin, Total bilirubin \\\u003C 1.5 mg\u002FdL ALT + AST levels ≤ 3 times above the upper normal limit\n\nExclusion Criteria:\n\n* Any concurrent and\u002For other active malignancy that has required systemic treatment within 2 years of the first dose of treatment.\n* For NSCLC: presence of activating EGFR, ALK, ROS1, RET, NTRK alterations linked to an approved first-line targeted drug.","ALL","18 Years",{"count":20,"type":21},600,"ESTIMATED","OBSERVATIONAL","The NeutroFlow study is a multi-center clinical trial designed to develop a computational model that converts flow cytometry results into a prediction of clinical benefit. The study analyzes Ly6Ehi neutrophils in biological samples from patients treated with immune checkpoint inhibitors to evaluate their likelihood of benefiting from treatment. Blood samples are collected prior to treatment and used to support the ongoing development of the algorithm.",[25,26,27,28,29],"Non Small Cell Lung Cancer (NSCLC)","Melanoma (Skin Cancer)","Triple Negative Breast Cancer (TNBC)","RCC, Renal Cell Cancer","HNSCC",[31,32,33,34,35],"Immunotherapy","Biomarker","Neutrophils","Flow Cytometry","Immune checkpoint inhibitor","NOT_YET_RECRUITING","2025-11-20",{"date":39,"type":40},"2025-11-24","ACTUAL",{"date":42,"type":21},"2025-11-15",{"date":44,"type":21},"2028-05-30",{"name":46,"class":47},"OncoHost Ltd.","INDUSTRY",3,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100495809","predicting-responsiveness-in-oncology-patients-based-on-host-response-evaluation-during-anti-cancer-treatments-using-multiomics-100495809","NCT05736029","Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using Multiomics","PROPHETIC Extended - Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Extended Study.","PROPHETIC","Inclusion Criteria:\n\n* Provision of informed consent prior to any study-specific procedures.\n* Male or female aged at least 18 years.\n* ECOG PS - 0\u002F1-2.\n\nExclusion Criteria:\n\n* Any concurrent and\u002For other active malignancy that has required systemic treatment within 2 years of first dose of treatment.\n* Generalized impairment or mental incompetence that would render the patient unable to understand his\u002Fher participation in the study.",true,{"count":59,"type":21},350,"The goal of this exploratory study is understand the mechanisms of response to immunotherapy in Non-Small Cell Lung Cancer patients.\n\nThe investigators are going to search for correlation between specific biological features and response to immunotherapy, and to use those associations for developing an algorithm enabling to identify patients that could benefit from the immune check inhibitor based anti cancer treatment.\n\nPatients will provide biological samples before and during their treatment, and clinical data will be collected.",[62,63],"Non Small Cell Lung Cancer","Healthy","RECRUITING","2023-02-09",{"date":67,"type":40},"2023-02-21",{"date":69,"type":40},"2022-11-07",{"date":71,"type":21},"2028-06-30",{"name":46,"class":47},1,""]